Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression

Cancer Research

Volumn 66, Issue 14, 2006, Pages 7158-7166

  Deglesne, Pierre Antoine ^a   Chevallier, Nathalie ^b   Letestu, Rémi ^a   Baran Marszak, Fanny ^a   Beitar, Taoufik ^a   Salanoubat, Célia ^b   Sanhes, Laurence ^b   Nataf, Joelle ^b   Roger, Claudine ^a   Varin Blank, Nadine ^b   Ajchenbaum Cymbalista, Florence ^a,c  

^a UNIVERSITÉ PARIS 13   (France)

^b INSERM   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CYCLIN D2; CYCLIN DEPENDENT KINASE 4; IMMOBILIZED ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN M ANTIBODY; IMMUNOGLOBULIN MU CHAIN; PROTEIN KINASE ZAP 70;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; ENZYME INDUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; LEUKEMIA CELL; LIGATION; MUTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIBODIES, ANTI-IDIOTYPIC; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 4; CYCLINS; DISEASE PROGRESSION; G1 PHASE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LEUKEMIA, B-CELL, CHRONIC; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 33746924345     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0085     Document Type: Article

References (37)

1. Magnac C, Porcher H, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003;17:133-7.
2. Orchard JA, Ibbolson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-11.
3. Wiestner A, Rosenwald A, Barry TS, et al, ZAP-70 expression identifies a chronic lymphoeylic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile Blood 2000;101:4944-51.
4. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia Cancer 1987;60:2712-6.
5. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 1999;94:1848-54.
6. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immumol Today 1994;15:288-94.
7. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005;105:1678-85.
8. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-25.
9. Capello D, Guarini A, Berra E, et al. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. Leukemia 2004;18:1941-7.
10. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
11. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-38.
12. Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol 2004;5:317-27.
13. Diamant E, Keren Z, Melamed D. CD19 regulates positive selection and maturation in B lymphopoiesis: lack of CD19 imposes developmental arrest of immature B cells and consequential stimulation of receptor editing. Blood 2005;105:3247-54.
14. Khan WN, Alt FW, Gerstein RM, et al. Defective B cell development and function in Btk-deficient mice. Immunity 1995;3:283-99.
15. Solvason N, Wu WW, Kabra N, Wu X, Lees E, Howard MC. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes. J Exp Med 1996;184:407-17.
16. Glassford J, Holman M, Banerji L, et al. Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen Receptor. J Biol Chem 2001;276:41040-8.
17. Solvason N, Wu WW, Parry D, et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol 2000;12:631-8.
18. Lam EW, Glassford J, Banerji L, Thomas NS, Sicinski P, Klaus GG. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem 2000;275:3479-84.
19. Mohamedali A, Soeiro I, Lea NC, et al. Cyclin D2 controls B cell progenitor numbers. J Leukoc Biol 2003;74:1139-43.
20. Ulivieri C, Baldari CT. The BCR signalosome: where cell fate is decided. J Biol Regul Homeost Agents 2005;19:1-16.
21. Schweighoffer E, Vanes L, Mathiot A, Nakamura T, Tybulewicz VL. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003;18:523-33.
22. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
23. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
24. Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005;105:2036-41.
25. Chen L, Widliopl G, Huynh I, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-14.
26. Nedellec S, Renaudineau Y, Bordron A, et al. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J Immunol 2005;174:3749-56.
27. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005;105:4820-7.
28. Lanham S, Hamblin T, Oscier D, Ibbotson B, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CP38 expression in chronic lymphocytic leukemia. Blood 2003;101:1087-93.
29. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841-94.
30. Zupo S, Massara R, Dono M, et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000;95:1199-206.
31. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001;98:3050-7.
32. Pasquier B, Launay P, Kanamaru Y, et al. Identification of FcαRI as an inhibitory receptor that controls inflammation: dual role of FcR-γ ITAM. Immunity 2005;22:31-42.
33. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995;85:2870-6.
34. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchertbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 1998;91:4694-700.
35. Park CS, Choi YS. How do follicular dendritic cells interact intimately with B cells in the germinal centre? Immunology 2005;114:2-10.
36. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:22-47.
37. Hamblin TJ. Predicting Progression-ZAP-70 in CLL. N Engl J Med 2004;351:856-7.